Emgality (fremanezumab) is a migraine medication prescribed to reduce the number and severity of migraine attacks in adults. Although no single migraine treatment works for everyone, some people have ...
Eli Lilly and Company LLY announced that the FDA has granted approval to its CGRP antibody, Emgality injection (300 mg) for the preventive treatment of episodic cluster headache in adult patients.
INDIANAPOLIS, Aug. 5, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that Emgality® (galcanezumab-gnlm) met the primary and all key secondary outcomes in CONQUER, a Phase 3 ...
Emgality demonstrated robust efficacy for patients consistent with previous studies, although it did not achieve statistical superiority versus active comparator on the primary endpoint Emgality ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results